• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ArriVent BioPharma Inc.

    11/14/24 4:33:47 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVBP alert in real time by email
    SC 13G 1 p24-3174sc13g.htm ARRIVENT BIOPHARMA, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
     

    ArriVent BioPharma, Inc.

    (Name of Issuer)
     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)
     

    04272N102

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ý Rule 13d-1(d)
     
    (Page 1 of 6 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 04272N10213GPage 2 of 6 Pages

     

    1

    NAME OF REPORTING PERSON

    HHLR Advisors, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    -0-

    6

    SHARED VOTING POWER

    4,484,672 shares of Common Stock*

    7

    SOLE DISPOSITIVE POWER

    -0-

    8

    SHARED DISPOSITIVE POWER

    4,484,672 shares of Common Stock*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,484,672 shares of Common Stock*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    13.4%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

    * Consists of (i) 555,555 shares of Common Stock held by a fund managed by HHLR (as defined in Item 2(a) below) and (ii) 3,929,117 shares of Common Stock held by funds managed by HIM (as defined in Item 2(a) below). HHLR and HIM are under common control and share certain policies, personnel and resources.

     

    CUSIP No. 04272N10213GPage 3 of 6 Pages

     

    1

    NAME OF REPORTING PERSON

    Hillhouse Investment Management, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    -0-

    6

    SHARED VOTING POWER

    4,484,672 shares of Common Stock*

    7

    SOLE DISPOSITIVE POWER

    -0-

    8

    SHARED DISPOSITIVE POWER

    4,484,672 shares of Common Stock*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,484,672 shares of Common Stock*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    13.4%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

    * Consists of (i) 555,555 shares of Common Stock held by a fund managed by HHLR and (ii) 3,929,117 shares of Common Stock held by funds managed by HIM. HHLR and HIM are under common control and share certain policies, personnel and resources.

     

     

    CUSIP No. 04272N10213GPage 4 of 6 Pages

     

    Item 1(a). NAME OF ISSUER
      The name of the issuer is ArriVent BioPharma, Inc. (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
      The Company's principal executive office is located at 18 Campus Boulevard, Suite 100, Newtown Square, Pennsylvania 19073.

     

    Item 2(a). NAME OF PERSON FILING
      This Schedule 13G is filed by: (i) HHLR Advisors, Ltd., an exempted Cayman Islands company (“HHLR”) and (ii) Hillhouse Investment Management, Ltd, an exempted Cayman Islands company (“HIM”). The foregoing persons are hereinafter sometimes each referred to as a “Reporting Person” and collectively referred to as the “Reporting Persons.”
       
      HHLR acts as the sole investment manager of HHLR Fund, L.P. (“HHLR Fund”). HHLR is hereby deemed to be the beneficial owner of, and to control the voting and investment power of, the Common Stock (as defined in Item 2(d) below) held by HHLR Fund. HIM acts as the sole management company of each Hillhouse Venture Fund V, L.P. (“Venture Fund V”), Hillhouse Healthcare Fund, L.P. (“Healthcare Fund”) and Hillhouse Venture Fund VI, L.P. (“Venture Fund VI”). VSUM VI is wholly owned by Venture Fund V; VSUM VIII is wholly owned by Healthcare Fund; and ARVT is wholly owned by Venture Fund VI. HIM is hereby deemed to be the beneficial owner of, and to control the voting power of, the Common Stock held by VSUM VI, VSUM VIII and ARVT. HHLR and HIM are under common control and share certain policies, personnel and resources. Accordingly, each of HHLR and HIM reports on this Schedule 13G that it has shared voting and dispositive power of the Common Stock beneficially owned by each of HHLR and HIM.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of each of the Reporting Persons is Office #122, Windward 3 Building, Regatta Office Park, West Bay Road, Grand Cayman, Cayman Islands, KY1-9006.

     

    Item 2(c). CITIZENSHIP
      Cayman Islands

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Common Stock, $0.0001 par value per share (the “Common Stock”)

     

    Item 2(e). CUSIP NUMBER
      04272N102

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;

     

     

    CUSIP No. 04272N10213GPage 5 of 6 Pages

     

      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: __________________________________

     

    Item 4. OWNERSHIP
      The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 33,585,893 shares of Common Stock reported to be issued and outstanding as of August 12, 2024, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 14, 2024.
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons (and the footnotes thereto) and is incorporated herein by reference.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      See Item 2.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.

     

    Item 10. CERTIFICATION  
      Not applicable.

     

     

    CUSIP No. 04272N10213GPage 6 of 6 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 14, 2024

     

    HHLR Advisors, LTD.  
       
       
    /s/ Audrey Woon  
    Name:  Audrey Woon  
    Title:    Chief Compliance Officer  

     

    HILLHOUSE Investment MANAGEMENT, LTD.  
       
       
    /s/ Audrey Woon  
    Name:  Audrey Woon  
    Title:    Chief Compliance Officer  

     

     

    Get the next $AVBP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVBP

    DatePrice TargetRatingAnalyst
    7/10/2025$33.00Buy
    Goldman
    3/20/2025$37.00Buy
    B. Riley Securities
    3/10/2025$45.00Buy
    Guggenheim
    7/22/2024$35.00Outperform
    Oppenheimer
    4/30/2024$25.00Buy
    H.C. Wainwright
    2/20/2024$35.00Buy
    Jefferies
    2/20/2024$27.00Buy
    Goldman
    2/20/2024$30.00Buy
    Citigroup
    More analyst ratings

    $AVBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on ArriVent BioPharma with a new price target

    Goldman resumed coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $33.00

    7/10/25 8:52:29 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on ArriVent BioPharma with a new price target

    B. Riley Securities initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $37.00

    3/20/25 7:59:08 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on ArriVent BioPharma with a new price target

    Guggenheim initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $45.00

    3/10/25 7:18:09 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by ArriVent BioPharma Inc.

    SCHEDULE 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

    10/15/25 4:07:02 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent BioPharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)

    9/9/25 8:00:13 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ArriVent BioPharma Inc.

    SCHEDULE 13G/A - ArriVent BioPharma, Inc. (0001868279) (Subject)

    8/14/25 4:59:38 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ArriVent Appoints Brent S. Rice as Chief Commercial Officer

    NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry. "Brent brings a proven track record in launching novel therapies, building high-performing organizations, and leading strategic pipeline planning," said Bing Yao, Chairman and Chief Executive Officer of ArriVent. "We are excited to welcome h

    9/22/25 4:05:00 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

    16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed overall response rate (cORR) 68.2% and duration of response (DOR) 14.6 months by BICR in first-line patientsConfirmed CNS (central nervous system) responses with firmonertinib including complete responses (CRs) by BICRFirmonertinib rapidly decreased or cleared PACC circulating tumor DNA (ctDNA) in frontline patients across PACC mutation types (frequent, less frequent and compound PACC) consistent with broad PACC activityEnrollment of the first patient in the global pivotal Phase 3 ALPACCA study in first-line EGFR PACC mutant non-small cell

    9/9/25 8:00:00 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent BioPharma Reports Second Quarter 2025 Financial Results

    Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient in the Phase 1 Study for ARR-217 (MRG007), a CDH17 targeted ADC, in gastrointestinal tumors Top-line firmonertinib monotherapy data from global pivotal FURVENT Phase 3 study for first-line EGFR exon20 insertion mutant NSCLC projected to be in early 2026Cash and investments of $254.5 million as of June 30, 2025, in addition to $81.1 million raised in the public offering in July 2025, expected to fund our operating plan to mid-2027 NEWTOWN SQUARE, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Arri

    8/11/25 8:00:00 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Lachapelle Robin exercised 11,153 shares at a strike of $2.28, increasing direct ownership by 9% to 135,736 units (SEC Form 4)

    4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

    7/15/25 7:00:15 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Parsey Merdad

    4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

    6/20/25 7:33:08 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Peterson Kristine

    4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

    6/20/25 7:32:41 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    Leadership Updates

    Live Leadership Updates

    View All

    ArriVent Appoints Brent S. Rice as Chief Commercial Officer

    NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry. "Brent brings a proven track record in launching novel therapies, building high-performing organizations, and leading strategic pipeline planning," said Bing Yao, Chairman and Chief Executive Officer of ArriVent. "We are excited to welcome h

    9/22/25 4:05:00 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent BioPharma Reports First Quarter 2025 Financial Results

    Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results

    5/12/25 8:00:00 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

    NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings decades of executive experience leading global clinical development in the biopharmaceutical industry, most recently serving as Chief Medical Officer and Executive Vice President of Gilead Sciences, Inc. "Dr. Parsey is a seasoned executive who has driven therapeutic innovation and strategic growth at prominent pharmaceutical and biotech companies acr

    4/28/25 8:00:00 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ArriVent BioPharma Inc.

    SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

    12/4/24 4:32:39 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ArriVent BioPharma Inc.

    SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

    11/14/24 4:33:47 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ArriVent BioPharma Inc.

    SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

    11/12/24 2:45:16 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care